Press Releases

 
Press Releases
  Date Title and Summary View
Jan 30, 2013
AMES, Iowa, Jan. 30, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $11.40 per share, which was ...
Jan 29, 2013
AMES, Iowa, Jan. 29, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  The Company expects to grant the underwriters...
Jan 3, 2013
AMES, Iowa, Jan. 3, 2013 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for cancer patients, today announced the appointment of Mr. Brian Wiley as Vice President of Business Development.  In ...
Dec 13, 2012
AMES, Iowa, Dec. 13, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the results of a  Phase 1 dose escalation study with its proprietary HyperAcute Prostate Cancer Immunotherapy were published in the Journal of Immunotherapy.  The article, entitled "Cellular Immunotherapy Study of Prostate Cancer Patients and ...
Nov 14, 2012
AMES, Iowa, Nov. 14, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) today announced that the European Commission (EC) has designated HyperAcute-Pancreas® Immunotherapy (algenpantucel-L) as an orphan medicinal product under Regulation (EC) No. 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan...
Nov 7, 2012
AMES, Iowa, Nov. 7, 2012 /PRNewswire/ -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that Lota S. Zoth has accepted appointment to its Board of Directors and will act as Chair of its Audit Committee. Ms. Zoth was Chief Fi...
Oct 31, 2012
AMES, IA -- (Marketwire) -- 10/31/12 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today reported consolidated financial results for the third quarter of 2012. NewLink updated the status of its clinical development programs including its Hy...
Oct 10, 2012
AMES, Iowa, Oct. 10, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) announces launching of an open-label, randomized, multi-institutional Phase 3 study in patients with borderline resectable or locally advanced unresectable pancreatic cancer. The projected enrollment will be 280 subjects and patients will be randomized (1:1) to re...
Oct 3, 2012
AMES, Iowa, Oct. 3, 2012 /PRNewswire/ -- NewLink Genetics Corporation (Nasdaq: NLNK) announces the launching of an open-label, randomized, multi-institutional adaptive design Phase2B/3 study to evaluate efficacy of its tergenpumatucel-L (HyperAcute® Lung) product candidate in patients with progressive or relapsed Stage-IIIB/IV non-small cell l...
Oct 2, 2012
AMES, Iowa, Oct. 2, 2012 /PRNewswire/ -- NewLink Genetics (NASDAQ:NLNK) today announced that the company will be presenting at the 3rd Annual Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:30 p.m. EDT on October 4, 2012, at the New York Academy of Medicine in New York. Dr. Charles Link, NewLink's Cha...
Page: FirstPrevious ...
16
NextLast
= add release to Briefcase